Editorial: Non-cellular Immunotherapies in Pediatric Malignancies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Mar 7

PMID 38449864

Authors

Sarah Alexander

Paul Harker-Murray

Robert J Hayashi

Affiliations

Soon will be listed here.

References

Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

Parakh S, Lee S, Gan H, Scott A . Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers (Basel). 2022; 14(6). PMC: 8946248. DOI: 10.3390/cancers14061454. View

Mohd A, Mohd O, Alabdallat Y, Al Dwairy S, Ghannam R, Hanaqtah B . Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review. J Res Med Sci. 2023; 28:71. PMC: 10729685. DOI: 10.4103/jrms.jrms_727_22. View

Chergui A, Reagan J . Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress. Cancers (Basel). 2023; 15(16). PMC: 10453133. DOI: 10.3390/cancers15164137. View

Sgouros G, Bodei L, McDevitt M, Nedrow J . Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020; 19(9):589-608. PMC: 7390460. DOI: 10.1038/s41573-020-0073-9. View

Samadi M, Kamrani A, Nasiri H, Shomali N, Heris J, Shahabi P . Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study. Pathol Res Pract. 2023; 249:154732. DOI: 10.1016/j.prp.2023.154732. View

McClory S, Maude S . The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2023; 37(6):1041-1052. DOI: 10.1016/j.hoc.2023.06.003. View

Guo X, Wu Y, Xue Y, Xie N, Shen G . Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment. Front Immunol. 2023; 14:1291836. PMC: 10722299. DOI: 10.3389/fimmu.2023.1291836. View

Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K . DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016; 165:32-49. DOI: 10.1016/j.pharmthera.2016.05.004. View

10.

DeMaria P, Bilusic M . Cancer Vaccines. Hematol Oncol Clin North Am. 2019; 33(2):199-214. DOI: 10.1016/j.hoc.2018.12.001. View

11.

Drago J, Modi S, Chandarlapaty S . Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021; 18(6):327-344. PMC: 8287784. DOI: 10.1038/s41571-021-00470-8. View

12.

Davids M, Kim H, Bachireddy P, Costello C, Liguori R, Savell A . Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016; 375(2):143-53. PMC: 5149459. DOI: 10.1056/NEJMoa1601202. View

13.

Nijhof I, Casneuf T, van Velzen J, van Kessel B, Axel A, Syed K . CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016; 128(7):959-70. DOI: 10.1182/blood-2016-03-703439. View

14.

Aldeghaither D, Zahavi D, Murray J, Fertig E, Graham G, Zhang Y . A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res. 2018; 7(2):230-243. PMC: 6359950. DOI: 10.1158/2326-6066.CIR-18-0266. View

15.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

16.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

17.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

18.

Castellino S, Pei Q, Parsons S, Hodgson D, McCarten K, Horton T . Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022; 387(18):1649-1660. PMC: 9945772. DOI: 10.1056/NEJMoa2206660. View

19.

Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

20.

Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J . IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90(6):2188-95. View